Do not use fibrinolysis inhibitor-thrombin topical without first talking to your doctor if you are allergic to cows or products derived from cows.
Fibrinolysis inhibitor-thrombin topical is in the FDA pregnancy category C. This means
that it is not known whether it will be harmful to an unborn baby.
It is not known whether fibrinolysis inhibitor-thrombin topical will be harmful to a
nursing baby.
Fibrinolysis inhibitor-thrombin topical will be administered by a healthcare professional as a topical application.
Due to the indications for use and the method of application of fibrinolysis inhibitor-thrombin topical, missing a dose is not likely to occur.
Fibrinolysis inhibitor-thrombin topical is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although fibrinolysis inhibitor-thrombin topical is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with your doctor the risks and benefits of using fibrinolysis inhibitor-thrombin topical.
Contact your doctor if you develop fever, drowsiness, chills, runny nose, rash, joint pain, poor appetite, tiredness, nausea, vomiting, abdominal pain, dark-colored urine, or yellowing of the skin or eyes following treatment with fibrinolysis inhibitor-thrombin topical. These may be symptoms of infections that may occur due to use of this product.
Notify your doctor immediately if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to fibrinolysis inhibitor-thrombin topical.
Other side effects are not expected to occur with the use of fibrinolysis inhibitor-thrombin topical. Talk to your doctor if you experience any side effects from this medication.
Fibrinolysis inhibitor-thrombin topical is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although fibrinolysis inhibitor-thrombin topical is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with your doctor the risks and benefits of using fibrinolysis inhibitor-thrombin topical.
Contact your doctor if you develop fever, drowsiness, chills, runny nose, rash, joint pain, poor appetite, tiredness, nausea, vomiting, abdominal pain, dark-colored urine, or yellowing of the skin or eyes following treatment with fibrinolysis inhibitor-thrombin topical. These may be symptoms of infections that may occur due to use of this product.
There are no restrictions on food, beverages, or activity following the use of fibrinolysis inhibitor-thrombin topical, unless otherwise directed by your doctor.
It is not known whether other medications will interact with fibrinolysis inhibitor-thrombin topical. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products during treatment with fibrinolysis inhibitor-thrombin topical.
Due to the indications for use and the method of application of fibrinolysis inhibitor-thrombin topical, an overdose of the medication is unlikely to occur. Contact your doctor or a poison control center for advice if an overdose is suspected.